A review of animal models utilized in preclinical studies of approved gene therapy products: trends and insights

Table 4 Animal models utilized in preclinical studies of products related to infectious diseases

Year of Approval	Trade name (General name)	Target cell (in vivo/ex-vivo	Indication	Animal model	Details	Comments	Category	References
1998	Vitravene	In vivo	Local treatment of cytomegalovirus retinitis in immunocompromised patients	Monkey	N/A	Systematic—Treated for every other week up to 3 months—Investigating the metabolites in liver, kidney, and plasma	N/A	[87,88,89]
1998	Vitravene	In vivo	Local treatment of cytomegalovirus retinitis in immunocompromised patients	Rabbit	N/A	Local—Monitoring for safety, also metabolism and elimination were investigated	N/A	[87,88,89]
2020	Spikevax	In vivo	COVID-19 vaccination	Monkey	N/A	Were injected intramuscularly with 10 μg or 100 μg in a 1 ml of 1 × phosphate-buffered saline (PBS) of the mRNA1273 vaccine	disease induction	[90]
2020	Comirnaty	In vivo	COVID-19 vaccination	Monkey	N/A	No more information was found for this product	disease induction	[91]

ISSN: 2233-7660